"Cyclin-Dependent Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Protein kinases that control cell cycle progression in all eukaryotes and require physical association with CYCLINS to achieve full enzymatic activity. Cyclin-dependent kinases are regulated by phosphorylation and dephosphorylation events.
| Descriptor ID |
D018844
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.646.500 D12.644.360.250 D12.776.167.200 D12.776.476.250
|
| Concept/Terms |
Cyclin-Dependent Kinases- Cyclin-Dependent Kinases
- Cyclin Dependent Kinases
- Cyclin-Dependent Protein Kinases
- Cyclin Dependent Protein Kinases
- cdk Proteins
|
Below are MeSH descriptors whose meaning is more general than "Cyclin-Dependent Kinases".
Below are MeSH descriptors whose meaning is more specific than "Cyclin-Dependent Kinases".
This graph shows the total number of publications written about "Cyclin-Dependent Kinases" by people in this website by year, and whether "Cyclin-Dependent Kinases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 3 | 5 | 8 |
| 2018 | 1 | 2 | 3 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Cyclin-Dependent Kinases" by people in Profiles.
-
Cyclin-dependent Kinases as Emerging Targets for Developing Novel Antiviral Therapeutics. Trends Microbiol. 2021 09; 29(9):836-848.
-
Cyclin dependent kinase inhibitors as a new potential therapeutic option in management of COVID-19. Med Hypotheses. 2021 01; 146:110380.
-
The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell. 2020 08 06; 182(3):685-712.e19.
-
The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges. Pharmacol Ther. 2020 09; 213:107579.
-
PCK1 negatively regulates cell cycle progression and hepatoma cell proliferation via the AMPK/p27Kip1 axis. J Exp Clin Cancer Res. 2019 Feb 04; 38(1):50.
-
Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13. Elife. 2018 11 13; 7.
-
The aryl hydrocarbon receptor and interferon gamma generate antiviral states via transcriptional repression. Elife. 2018 08 22; 7.
-
Dysregulation of miRNA in chronic hepatitis B is associated with hepatocellular carcinoma risk after nucleos(t)ide analogue treatment. Cancer Lett. 2018 10 10; 434:91-100.
-
Genetic and pharmacological inhibition of microRNA-92a maintains podocyte cell cycle quiescence and limits crescentic glomerulonephritis. Nat Commun. 2017 11 28; 8(1):1829.
-
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet. 2017 Dec; 49(12):1693-1704.